Research Analysts Offer Predictions for ORMP Q2 Earnings

Key Points

• Zacks Small Cap has downgraded Oramed Pharmaceuticals' Q2 2025 earnings per share estimate from ($0.01) to ($0.04), signaling a negative outlook for the biotechnology company.
• Wall Street Zen has also lowered their rating on Oramed Pharmaceuticals from a "hold" to a "sell", indicating growing concerns among analysts.
• Oramed Pharmaceuticals recently reported a quarterly EPS of ($0.19), significantly missing analysts' expectations, and had revenues of $2.00 million for the quarter.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Zacks Small Cap lowered their Q2 2025 earnings estimates for shares of Oramed Pharmaceuticals in a research note issued on Monday, July 28th. Zacks Small Cap analyst M. Marin now anticipates that the biotechnology company will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Oramed Pharmaceuticals' current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals' Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.34) EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The business had revenue of $2.00 million for the quarter.

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th.

Oramed Pharmaceuticals Stock Performance

NASDAQ ORMP remained flat at $2.12 during trading hours on Thursday. 57,539 shares of the company were exchanged, compared to its average volume of 146,941. The company has a market cap of $86.59 million, a price-to-earnings ratio of -4.82 and a beta of 1.61. The business's 50-day simple moving average is $2.18 and its 200-day simple moving average is $2.23. Oramed Pharmaceuticals has a one year low of $1.82 and a one year high of $3.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC raised its position in shares of Oramed Pharmaceuticals by 36.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 5,000 shares during the last quarter. N.E.W. Advisory Services LLC raised its position in shares of Oramed Pharmaceuticals by 52.9% in the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 6,540 shares during the last quarter. Boothbay Fund Management LLC raised its position in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares during the last quarter. Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares during the last quarter. Finally, Peapod Lane Capital LLC raised its position in shares of Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.